Original Research

Combination of Cerebral Computed Tomography and Simplified Cardiac Arrest Hospital Prognosis (sCAHP) Score for Predicting Neurological Recovery in Cardiac Arrest Survivors

Sih-Shiang Huang¹, Yu-Tzu Tien¹, Hsin-Yu Lee¹, Hooi-Nee Ong¹, Chien-Hua Huang¹, Wei-Ting Chen¹, Wen-Jone Chen^{1,2,3}, Wei-Tien Chang¹, Min-Shan Tsai^{1,*}

Academic Editor: Zhonghua Sun

Submitted: 8 October 2022 Revised: 20 November 2022 Accepted: 30 November 2022 Published: 12 January 2023

Abstract

Background: Cerebral computed tomography (CT) and various severity scoring systems have been developed for the early prediction of the neurological outcomes of cardiac arrest survivors. However, few studies have combined these approaches. Therefore, we evaluated the value of the combination of cerebral CT and severity score for neuroprognostication. **Methods:** This single-center, retrospective observational study included consecutive patients surviving nontraumatic cardiac arrest (January 2016 and December 2020). Gray-to-white ratio (GWR), third and fourth ventricle characteristics, and medial temporal lobe atrophy scores were evaluated on noncontrast cerebral CT. Simplified cardiac arrest hospital prognosis (sCAHP) score was calculated for severity assessment. The associations between the CT characteristics, sCAHP score and neurological outcomes were analyzed. **Results:** This study enrolled 559 patients. Of them, 194 (34.7%) were discharged with favorable neurological outcomes. Patients with favorable neurological outcome had a higher GWR (1.37 vs 1.25, p < 0.001), area of fourth ventricle (461 vs 413 mm², p < 0.001), anteroposterior diameter of fourth ventricle (0.95 vs 0.86 cm, p < 0.001) and a lower sCAHP score (146 vs 190, p < 0.001) than those with poor recovery. Patients with higher sCAHP score had lower GWR (p trend q < 0.001), area of fourth ventricle (p trend q < 0.001) and anteroposterior diameter of fourth ventricle (p trend q < 0.001). The predictive ability by using area under receiver operating characteristic curve (AUC) for the combination of sCAHP score and GWR was significantly higher than that calculated for sCAHP (0.86 vs 0.76, p < 0.001) or GWR (0.86 vs 0.81, p = 0.001) alone. **Conclusions:** The combination of GWR and sCAHP score can be used to effectively predict the neurological outcomes of cardiac arrest survivors and thus ensure timely intervention for those at high risk of poor recovery.

Keywords: severity score; cardiac arrest; neuroprognostication; gray-to-white ratio; cerebral CT

1. Introduction

Sudden cardiac arrest remains a major challenge in clinical practice and accounts for more than 356,000 and 290,000 annual cases of out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA), respectively, in the United States [1,2]. In Taiwan, data from the National Health Insurance Administration indicate an OHCA incidence of 51.1 per 100,000 individuals [3]. Owing to hypoxic-ischemic brain injury after cardiac arrest, cognitive problems are common in cardiac arrest survivors [4]. Early and accurate prediction of the neurological outcomes of cardiac arrest survivors is crucial for determining the extent of medical resources required and for avoiding the inappropriate withdrawal of life-sustaining treatment for those with potential for favorable neurological recovery [5,6]. In addition, neurological recovery may be delayed after therapeutic temperature management (TTM) because of the use of sedatives [7,8]. Therefore, several tools have been developed for neuroprognostication for cardiac arrest survivors; these include brain imaging modalities, severity scores, electrophysiological monitoring data, and biomarkers [9].

Gray-to-white ratio (GWR), the ratio of gray matter to white matter on cerebral computed tomography (CT), has been explored as a marker of the severity of hypoxicischemic encephalopathy among cardiac arrest survivors [10-13]. Moreover, some ventricular characteristics detected on cerebral CT, such as the area of lateral ventricles, ventricle-to-brain ratio (VBR), anteroposterior diameters, and size of the third and fourth ventricles, have been used as predictive markers [14,15]. Medial temporal lobe atrophy (MTLA) scores help predict cognitive function [16], and the extent of brain atrophy has been recently used to predict the cognitive outcomes of OHCA survivors [17,18]. Some studies focused on using cerebral magnetic resonance imaging (MRI) for neurological outcome prediction in cardiac arrest survivors and showed prominent result [17–20]; however, most of the relevant studies had small sample sizes and the group of patients who had MRI-incompatible

¹Department of Emergency Medicine, National Taiwan University Medical College and Hospital, 100 Taipei, Taiwan

²Department of Internal Medicine (Cardiology division), National Taiwan University Medical College and Hospital, 100 Taipei, Taiwan

³Department of Internal Medicine, Min-Sheng General Hospital, 330 Taoyuan, Taiwan

^{*}Correspondence: mshanmshan@gmail.com (Min-Shan Tsai)

internal cardiac defibrillators would be excluded. In addition to brain image, several other electrophysiological monitoring and clinical scoring systems have been established for illness severity and prognostication. The somatosensory evoked potentials (SSEP) is now widely accepted as one of the multimodal approach tools for functional outcome prediction in cardiac arrest survivors. Some studies concluded that it may be the earliest predictor for favorable neurological outcomes; however, the self-fulfilling prophecy is still a major concern [21,22]. The simplified cardiac arrest hospital prognosis (sCAHP) score is a validated tool for the early prediction of poor neurological outcomes at hospital discharge [23,24]. sCAHP scores are advantageous over CAHP score in that they do not include a parameter corresponding to no-flow time, which is difficult to estimate for unwitnessed OHCA. GWR is one of the eight factors of the post-Cardiac Arrest Syndrome for Therapeutic Hypothermia (CAST) score for the early prediction of neurological outcomes after cardiac arrest [25]. A revised CAST score was proposed in which the calculation is simplified through the deletion of three of the eight CAST factors: GWR, albumin level, and hemoglobin level [26]. In a single-center retrospective study, the two scores, with and without GWR, were compared, but no substantial differences were noted in the prognostic value of the two scores [27]. Limited evidence is available to indicate whether GWR still plays a crucial role in overall interpretation in addition to severity score for the neuroprognostication. Furthermore, the correlations between cerebral CT parameters and severity scores remain unclear. Therefore, we investigated whether predictive markers from cerebral CT are correlated with arrest severity scores. In addition, we evaluated the benefits of combining neuroimaging data with severity scores for predicting the neurological outcomes of cardiac arrest survivors.

2. Materials and Methods

2.1 Study Design and Patients

The retrospective observational study, approved by the Institutional Review Boards of National Taiwan University Hospital (NTUH) (202112205RINB), enrolled 1133 non-traumatic adult cardiac arrest patients between January 2016 to December 2020 at a single tertiary medical center in Taipei, Taiwan, and the requirement of informed consent was waived. After excluding patients without sustained return of spontaneous circulation (ROSC) (n = 547) and without cerebral CT within 24 h after ROSC, there were 577 nontraumatic adult cardiac arrest survivors who underwent cerebral CT within 24 h after ROSC. Patients whose cerebral CT images were unsuitable for interpretation or measurement (n = 10) and those whose cerebral CT findings revealed intracranial hemorrhage (n = 8) were excluded. Finally, 559 patients were included. Of them, 194 patients (34.7%) were discharged with favorable neurological outcomes, defined as a score of 1 or 2 on the

Glasgow–Pittsburgh cerebral performance category (CPC) scale, and constituted the favorable outcome group. The remaining 365 patients exhibited poor neurological recovery (CPC score of 3–5) at discharge and constituted the poor outcome group (Fig. 1).




Fig. 1. Flowchart of patient enrollment. CPR, cardiopulmonary resuscitation; CT, computed tomography; ED, emergency department; ROSC, return of spontaneous circulation.

2.2 Data Collection

The patients' underlying characteristics, disease severity, cardiac arrest events, and postarrest care were collected from medical records by using a predesigned questionnaire based on the Utstein Style [28]. OHCA was defined as the absence of circulation outside the hospital, and IHCA was defined as the absence of circulation after triage. Transferred patients with cardiac arrest were defined as those patients who were successfully resuscitated at another hospital and then transferred to NTUH. Prehospital ROSC was defined as the return of the heartbeat and pulse in patients with OHCA before their arrival at the hospital, as evident from their emergency medical service records. Ischemic heart disease, heart failure, structural heart disease, or arrhythmia without considerable electrolyte imbalance was regarded as the primary cause of cardiac arrest. The causes of cardiac arrest were determined by responsible primary care physicians who were blinded to the group allocation. To evaluate cardiac arrest severity at ROSC, the sCAHP score was calculated [23]. The TTM protocol at NTUH includes reducing the patient's body temperature to a target temperature (33 °C) within 6 h after ROSC, maintaining the target temperature for 24 h, rewarming the patient by gradually increasing (0.25 °C/h; using BD Arctic Sun 5000 Temperature Management System (Franklin Lakes, NJ, USA) with automated feedback) the body temperature to 36 °C, and maintaining the body temperature at <36.5 °C for 24 h after complete rewarming. The highest acute physiology and chronic health evaluation (APACHE) II score within 24 h after ROSC was recorded.



2.3 Cerebral CT Measurements

Noncontrast cerebral CT images obtained using a 64slice CT scanner (5-mm slice; LightSpeed, GE Healthcare, Chicago, IL, USA) were analyzed by two investigators (SSH and HYL) who were blinded to the final neurological outcomes. The investigators measured the Hounsfield unit (HU) values of the putamen and corpus callosum at the level of the basal ganglia [13] as well as the anteroposterior diameter of the fourth ventricle. In addition, the patients' MTLA scores were obtained from the National Taiwan University hospital's picture archiving and communication system [29]. The MTLA score is a radiographic evaluation of brain atrophy. Abnormal MTLA scores were defined as scores of ≥ 2 in patients aged ≤ 75 years and scores of ≥ 3 in patients aged ≥75 years. GWR was calculated as the ratio of the average HU value of the bilateral putamen to that of the bilateral corpus callosum. To determine the areas of the entire brain, lateral ventricles, and third and fourth ventricles, MIPAV (http://mipav.cit.nih.gov/ 11.0.7, Center for Information Technology, National Institutes of Health at Bethesda, MD, USA) was used. The region of interest was drawn adjacent to the target structure to calculate the area in square millimeters [30]. VBR was calculated as the ratio of the total area of the two lateral ventricles to that of the entire brain.

2.4 Statistical Analysis

Categorical variables were compared using the chisquare or Fisher's exact test and are expressed in terms of numbers and percentages. Continuous variables were compared using the Mann-Whitney U test and are expressed in terms of medians and interquartile ranges. p values for trends (p trend) were calculated to evaluate the differences in the CT characteristics of the aforementioned groups. Receiver operating characteristic (ROC) curves were plotted, and the areas under the ROC curves (AUCs) were calculated to evaluate the performance of GWR in predicting neurological outcomes. The DeLong test was performed to compare the ROC curves. Statistical significance was set at p < 0.05. All data were analyzed using R 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria).

3. Results

The median age of the study cohort was 66.4 (55.0–77.3) years, and 395 (70.7%) of the patients were men. The numbers of patients with OHCA, patients with IHCA, and transferred patients were 348 (62.2%), 162 (29.0%), and 49 (8.8%), respectively. Most of the patients (482; 86.2%) had witnessed collapse, and 35.1% had initial shockable rhythms.

Table 1 summarizes the demographic characteristics of the cardiac arrest survivors. The favorable outcome group was younger than the poor outcome group (61.3 vs 68.7 years, p < 0.001). Regarding their underlying characteristics, no marked differences were noted between the

groups except in malignancy, which was more prevalent in the poor outcome group than in the favorable outcome group (28.2 vs 13.4%, p < 0.001). Regarding cardiac events, compared with those of the poor outcome group, the favorable outcome group had more prehospital ROSC (6.8 vs 25.8%, p < 0.001), and fewer total cardiopulmonary resuscitation (CPR) duration (15.2 vs 25.4 min, p < 0.001), CPR >10 min (95.3 vs 86.6%, p < 0.001), repeated CPR (23.6 vs 11.9%, p = 0.001), or Epinephrine ≥ 3 mg during resuscitation (50.7 vs 23.2%, p < 0.001). More patients in the favorable neurological outcome groups were classified as low severity in the sCAHP score (52.2 vs 15.9%, p <0.001). Similarly, there was higher proportion of patients with high severity in the poor outcome group than in the favorable outcome group (40.0 vs 9.3%, p < 0.001). Regarding postarrest care, compared with the poor outcome group, the favorable outcome group had higher systolic blood pressure (132 vs 114 mmHg, p < 0.001), diastolic blood pressure (79.0 vs 64.5 mmHg, p < 0.001), hemoglobin levels (14.3 vs 12.0 g/dL, p < 0.001), and pH (7.20 vs 7.08, p <0.001). Compared with the favorable outcome group, the poor outcome group exhibited higher APACHE II scores (35 vs 30, p < 0.001), high-sensitivity troponin-T levels (53.4 vs 25.8 ng/L, p < 0.001), and lactic acid levels (9.84)vs 8.04 mmol/L, p < 0.001).

Table 2 summarizes the cerebral CT characteristics of each group. The test-retest reliability of the neuroimaging measurements was characterized by excellent intraclass and interrater correlation coefficients of 0.960 and 0.909, respectively. Compared with the poor outcome group, the favorable outcome group had a significantly higher GWR (1.37 vs 1.25, p < 0.001) and anteroposterior diameter of the fourth ventricle (0.95 vs 0.86 cm, p < 0.001). The fourth ventricle area was larger in the favorable outcome group than in the poor outcome group (461 vs 413 mm 2 , p< 0.001). However, no significant differences were noted between the groups in lateral ventricle area, third ventricle area, VBR or abnormal MTLA score. The cerebral CT characteristics were compared between groups stratified by sCAHP score (Table 3). Significantly lower GWR (p trend < 0.001), lower area (p trend = 0.019) and anteroposterior diameter (p trend = 0.014) of the fourth ventricle were associated with higher illness severity.

Table 4 presents the ability of GWR and sCAHP score in predicting neurological outcomes. The AUC was 0.81 (0.78–0.85) for GWR and 0.76 (0.72–0.80) for sCAHP score; no significant differences were noted (p=0.065). The combination of GWR and sCAHP score exhibited significantly higher prognostication performance than either individual marker (GWR vs combination: p=0.001; sC-AHP vs combination: p<0.001; Fig. 2) and exhibited greater predictive accuracy for subgroups of patients with OHCA, those with initial nonshockable rhythm, and those receiving TTM.



Table 1. Baseline characteristics of studied patients.

Male, n (%) All patients Favorable outcome Positructure	Table 1. Baseline characteristics of studied patients.				
Male, n (%) 395 (70.7) 143 (73.7) 252 (69.0) 0.291 Age ≥65 years 308 (551.) 80 (41.2) 228 (62.5) <0.001 Age, years, median (IQR) 66.4 (55.0 -77.3) 61.3 (51.1 -72.1) 68.7 (57.8 -79.4) <0.001 Medrying characteristics, n(%) 131 (56.5) 109 (56.2) 207 (56.7) 0.976 Diabetes mellitus 177 (31.7) 54 (27.8) 123 (33.7) 0.186 Hypertipidemia 64 (11.4) 26 (13.4) 38 (10.4) 0.359 Coronary atrey disease 190 (34.0) 57 (29.4) 133 (36.4) 0.113 Heart failure 54 (9.7) 18 (9.3) 36 (9.9) 0.942 Valvular heart disease 18 (3.2) 7 (3.6) 11 (3.0) 0.899 Arrhythmia 75 (13.4) 32 (16.5) 43 (11.8) 0.154 COPD/Asthma 53 (9.5) 17 (8.8) 36 (9.9) 0.786 Post-tracheostomy 11 (2.0) 2 (1.0) 9 (2.5) 0.399 Renal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignaney 129 (23.1) 26 (13.4) 103 (28.2) 0.001 Cardiac arrest events, n(%) 10 (3.6) 92 (25.2) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Pre-hospital ROSC 10 (10.9) 13 (8.6) 144 (3.9.5) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Pre-hospital ROSC 10 (10.9) 13 (8.6) 14 (4.9.5) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Pre-hospital ROSC 10 (10.9) 13 (8.6) 14 (4.9.5) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Repeated CPR 109 (19.5) 132 (10.9 (10.5) 14 (40.0) 0.001		All patients	Favorable outcome	Poor outcome	<i>p</i> -value
Age ≥ 65 years 308 (55.1) 80 (41.2) 228 (62.5) <0.001		(n = 559)	(n = 194)	(n = 365)	r
Age, years, median (IQR) 66.4 (55.0-77.3) 61.3 (51.1-72.1) 68.7 (57.8-79.4) <0.001 Underlying characteristics, n(W) Hypertension 316 (56.5) 109 (56.2) 207 (56.7) 0.976 Diabetes mellitus 177 (31.7) 54 (27.8) 123 (33.7) 0.186 Hypertipidemia 64 (11.4) 26 (13.4) 38 (10.4) 0.359 Coronary artery disease 190 (34.0) 57 (29.4) 133 (36.4) 0.113 Heart failure 54 (9.7) 18 (9.3) 36 (9.9) 0.942 Valvular heart disease 18 (3.2) 7 (3.6) 11 (3.0) 0.899 Arrhythmia 75 (13.4) 32 (16.5) 43 (11.8) 0.154 COPD/Asthma 53 (9.5) 17 (8.8) 36 (9.9) 0.786 Post-tracheostomy 11 (2.0) 2 (1.0) 9 (2.5) 0.399 Remal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2	Male, n (%)	395 (70.7)	143 (73.7)	252 (69.0)	0.291
Underlying characteristics, n(%) Hypertension 316 (56.5) 109 (56.2) 207 (56.7) 0.976 Diabetes mellitus 177 (31.7) 54 (27.8) 123 (33.7) 0.186 Hyperlipidemia 64 (11.4) 26 (13.4) 38 (10.4) 0.359 Coronary artery disease 190 (34.0) 57 (29.4) 133 (36.4) 0.113 Heart failure 54 (9.7) 18 (9.3) 36 (9.9) 0.942 Valvular heart disease 18 (3.2) 7 (3.6) 11 (3.0) 0.889 Arrhythmia 75 (13.4) 32 (16.5) 43 (11.8) 0.154 COPD/Asthma 53 (9.5) 17 (8.8) 36 (9.9) 0.786 Post-tracheostomy 11 (2.0) 2 (1.0) 9 (2.5) 0.399 Renal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (21.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) 0.001 Cardica arrest events, n(%) Source 0HCA 348 (62.2) 123 (63.4) 225 (61.6) HHCA 162 (29.0) 59 (30.4) 103 (28.2) Transfer 49 (8.8) 12 (6.2) 37 (10.1) Witnessed collapse 482 (86.2) 179 (92.3) 303 (83.0) 0.004 Initial shockable rhythm 19 (635.1) 104 (53.6) 92 (25.2) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) 0.001 CPR >10 min 516 (92.3) 168 (86.6) 348 (95.3) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) 0.001 CPR >10 min 516 (92.3) 18 (80.6) 169 (46.3) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Repeated CPR 109 (19.5) 13 (18.9) 145 (39.7) 0.250 High (>200) 159 (28.4) 101 (32.1) \$8 (15.9) 0.001 Repeated CPR 109 (19.5) 13 (18.9) 146 (40.0) 0.001 Repeated CPR 109 (19.5) 13 (18.9) 146 (40.0) 0.0001 Repeated CPR 109 (19.5) 13 (19.9) 145 (39.7) 0.250 High (>200) 159 (28.4) 101 (32.1) \$8 (15.9) 0.001 Repeated CPR 109 (19.5) 14 (30.9) 14 (40.9) 0.001 ROSC DBP, mmHg 69 (54.0-88.5) 79 (62.0-94.5) 64.5 (50.0-84.0) 0.001 Pro-toppin-Ting 23 mg (24.0) 13 (66.34.0) 144 (39.5) 0.024 APACHE II score 34 (27.5-39.0) 30 (19.5-36.0) 35 (31-40) 0.001 Hemoglobin, g/dL 12.6 (10.3-15.1	Age ≥65 years	308 (55.1)	80 (41.2)	228 (62.5)	< 0.001
Hypertension 316 (56.5) 109 (56.2) 207 (56.7) 0.976 Diabetes mellitus 177 (31.7) 54 (27.8) 123 (33.7) 0.186 Hyperlipidemia 64 (11.4) 26 (13.4) 38 (10.4) 0.359 Coronary artery disease 190 (34.0) 57 (29.4) 133 (36.4) 0.113 Heart failure 54 (9.7) 18 (9.3) 36 (9.9) 0.942 Valvular heart disease 18 (3.2) 7 (3.6) 11 (3.0) 0.899 Arrhythmia 75 (13.4) 32 (16.5) 43 (11.8) 0.154 COPD/Asthma 53 (9.5) 17 (8.8) 36 (9.9) 0.786 Post-tracheostomy 11 (2.0) 2 (1.0) 9 (2.5) 0.399 Renal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) 0.001 Cardiac arrest events, n(%) Source 0HCA 348 (62.2) 123 (63.4) 225 (61.6) HCA 162 (29.0) 59 (30.4) 103 (28.2) Transfer 49 (8.8) 12 (6.2) 37 (10.1) Witnessed collapse 482 (86.2) 179 (92.3) 303 (83.0) 0.004 Initial shockable rhythm 196 (35.1) 104 (53.6) 92 (25.2) 0.001 Total CPR duration (min) 21.9 ± 7.3 15.2 ± 6.0 25.4 ± 7.6 0.001 CPR > 10 min 516 (92.3) 168 (86.6) 348 (93.5) 0.001 Epinephrine ≥ 3 mg 230 (41.1) 45 (23.2) 185 (50.7) 0.001 CRR Source 109 (19.5) 23 (11.9) 86 (23.6) 0.001 CPR > 10 min 516 (92.3) 18 (8.6) 169 (46.3) 0.001 SCAHP severity Low (<150) 159 (28.4) 101 (52.1) 58 (15.9) 0.001 ROSC DBP, mmHg 69 (54.0-88.5) 79 (62.0-94.5) 64.5 (50.0-84.0) 0.001 TTM 210 (37.6) 66 (34.0) 144 (33.5) 0.250 High (>20.0) 164 (29.3) 18 (9.3) 146 (40.0) 0.0001 TTM 210 (37.6) 66 (34.0) 144 (33.5) 0.001 Hemoglobin, g/dL 12.6 (10.3-15.1) 14.3 (11.0-16.0) 12.0 (9.7-14.4) 0.001 Troponin-T, ng/L 36.4 (16.0-116) 25.8 (14.3-17.1) 53.4 (20.1-14.2) 0.001 Hemoglobin, g/dL 12.6 (10.3-15.1) 14.3 (11.0-16.0) 12.0 (9.7-14.4) 0.001 Troponin-T, ng/L 36.4 (16.0-116) 25.8 (14.3-17.1) 53.4 (20.1-14.2) 0.0001 Hemoglobin, g/dL 7.1 (27.00-7.25) 7.20 (7.05-7.29) 7.08 (6.90-7.20) 0.0001	Age, years, median (IQR)	66.4 (55.0–77.3)	61.3 (51.1–72.1)	68.7 (57.8–79.4)	< 0.001
Diabetes mellitus 177 (31.7) 54 (27.8) 123 (33.7) 0.186 Hyperlipidemia 64 (11.4) 26 (13.4) 38 (10.4) 0.359 Coronary artery disease 190 (34.0) 57 (29.4) 133 (36.4) 0.113 Heart failure 54 (9.7) 18 (9.3) 36 (9.9) 0.942 Valvular heart disease 18 (3.2) 7 (3.6) 11 (3.0) 0.899 Arrhythmia 75 (13.4) 32 (16.5) 43 (11.8) 0.154 COPD/Asthma 53 (9.5) 17 (8.8) 36 (9.9) 0.786 Post-tracheostomy 11 (2.0) 2 (1.0) 9 (2.5) 0.399 Renal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.403 Maliganacy 129 (23.1)	Underlying characteristics, n(%)				
Hyperlipidemia $64 (11.4)$ $26 (13.4)$ $38 (10.4)$ 0.359 Coronary artery disease $190 (34.0)$ $57 (29.4)$ $133 (36.4)$ 0.113 Heart failure $54 (9.7)$ $18 (9.3)$ $36 (9.9)$ 0.942 Valvular heart disease $18 (3.2)$ $7 (3.6)$ $11 (3.0)$ 0.899 Arrhythmia $75 (13.4)$ $32 (16.5)$ $43 (11.8)$ 0.154 COPD/Asthma $53 (9.5)$ $17 (8.8)$ $36 (9.9)$ 0.786 Post-trackostomy $11 (2.0)$ $2 (1.0)$ $9 (2.5)$ 0.399 Renal disease $49 (8.8)$ $18 (9.3)$ $31 (8.5)$ 0.877 ESRD $61 (10.9)$ $22 (11.3)$ $39 (10.7)$ 0.925 Liver cirrhosis $11 (2.0)$ $1 (0.5)$ $10 (2.7)$ 0.138 CVA $50 (8.9)$ $15 (7.7)$ $35 (9.6)$ 0.564 Dementia $19 (3.4)$ $4 (2.1)$ $15 (4.1)$ 0.305 Bedridden $21 (3.8)$ $5 (2.6)$ $16 (4.4)$ 0.403 Malignancy $129 (23.1)$ $26 (13.4)$ $103 (28.2)$ 0.001 Cardiae arrest events, $n(\%)$ Source 0.001 0.004 0.003 0.004 0.004 0.003 0.004 0.004 0.004 0.003 0.004 0.004 0.004 0.003 0.004 0.004 0.004 0.004 0.004 0.004 0.005 0.004 0.004 0.005 0.004 0.004 0.004 0.005 0.004 0.004 0.005 0.006 0.004 0.006 0.004 0.006 $0.$	Hypertension	316 (56.5)	109 (56.2)	207 (56.7)	0.976
Coronary artery disease H90 (34.0) 57 (29.4) 133 (36.4) 0.113 Heart failure 54 (9.7) 18 (9.3) 36 (9.9) 0.942 Valvular heart disease 18 (3.2) 7 (3.6) 11 (3.0) 0.899 Arrhythmia 75 (13.4) 32 (16.5) 43 (11.8) 0.154 COPD/Asthma 53 (9.5) 17 (8.8) 36 (9.9) 0.786 Post-tracheostomy 11 (2.0) 2 (1.0) 9 (2.5) 0.399 Renal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) 0.001 Cardiac arrest events, n(%) Source 0HCA 348 (62.2) 123 (63.4) 225 (61.6) HCA 162 (29.0) 59 (30.4) 103 (28.2) 17 mrsfer 49 (8.8) 12 (6.2) 37 (10.1) Witnessed collapse 482 (86.2) 179 (92.3) 303 (83.0) 0.004 Initial shockable rhythm 196 (35.1) 104 (53.6) 92 (25.2) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 185 (50.7) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Cardiogenic arrest 302 (54.0) 133 (68.6) 348 (95.3) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Cardiogenic arrest 302 (54.0) 133 (68.6) 169 (46.3) 0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Cardiogenic arrest 302 (54.0) 133 (68.6) 169 (46.3) 0.001 TTM 2000 164 (29.3) 18 (9.3) 146 (40.0) 0.001 Prota-arrest care, median (IQR) ROSC SPR, mmHg 119 (99-154) 132 (104-161) 114 (84.0-149) 0.001 TTM 210 (37.6) 66 (34.0) 144 (39.5) 0.242 APACHE II score 34 (27.5-39.0) 30 (19.5-36.0) 35 (31-40) 0.001 Hemglobin, g/dL 12.6 (10.3-15.1) 14.3 (11.0-16.0) 12.0 (9.7-14.4) 0.001 TTM 210 (37.6) 66 (34.0) 144 (39.5) 0.242 APACHE II score 34 (27.5-39.0) 30 (19.5-36.0) 35 (31-40) 0.001 Hemglobin, g/dL 12.6 (10.3-15.1) 14.3 (11.0-16.0) 13.4 (0.0-11-40) 0.001 Hemglobin, g/dL 12.6 (10.3-15.1)		177 (31.7)	54 (27.8)	123 (33.7)	0.186
Heart failure $(54 (9.7))$ $($	• • •	64 (11.4)	26 (13.4)	38 (10.4)	0.359
Valvular heart disease 18 (3.2) 7 (3.6) 11 (3.0) 0.899 Arrhythmia 75 (13.4) 32 (16.5) 43 (11.8) 0.154 COPD/Asthma 53 (9.5) 17 (8.8) 36 (9.9) 0.786 Post-tracheostomy 11 (2.0) 2 (1.0) 9 (2.5) 0.399 Renal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) <0.001		190 (34.0)	57 (29.4)	` '	
Arrhythmia 75 (13.4) 32 (16.5) 43 (11.8) 0.154 COPD/Asthma 53 (9.5) 17 (8.8) 36 (9.9) 0.786 Post-tracheostomy 11 (2.0) 2 (1.0) 9 (2.5) 0.399 Renal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) <0.001 Cardiac arrest events, n(%) Source 0.561 OHCA 348 (62.2) 123 (63.4) 225 (61.6) IHCA 162 (29.0) 59 (30.4) 103 (28.2) Transfer 49 (8.8) 12 (6.2) 37 (10.1) Witnessed collapse 482 (86.2) 179 (92.3) 303 (83.0) 0.004 Initial shockable rhythm 196 (35.1) 104 (33.6) 92 (25.2) <0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) <0.001 Total CPR duration (min) 21.9 ± 7.3 15.2 ± 6.0 25.4 ± 7.6 <0.001 CPR >10 min 516 (92.3) 168 (86.6) 348 (95.3) <0.001 Repetaed CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 CPR >10 min 516 (92.3) 180 (86.6) 348 (95.3) <0.001 Repetaed CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 CARTion (10 1 1 4 5 (23.2) 185 (50.7) <0.001 CARTion (10 1 1 4 5 (23.2) 185 (50.7) <0.001 CARTion (10 1 1 1 4 5 (23.2) 185 (50.7) <0.001 CARTion (10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		54 (9.7)	18 (9.3)	36 (9.9)	
COPD/Asthma 53 (9.5) 17 (8.8) 36 (9.9) 0.786 Post-tracheostomy 11 (2.0) 2 (1.0) 9 (2.5) 0.399 Renal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) <0.001		18 (3.2)	7 (3.6)	11 (3.0)	0.899
Post-tracheostomy					0.154
Renal disease 49 (8.8) 18 (9.3) 31 (8.5) 0.877 ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) <0.001		53 (9.5)	17 (8.8)	36 (9.9)	0.786
ESRD 61 (10.9) 22 (11.3) 39 (10.7) 0.925 Liver cirrhosis 11 (2.0) 1 (0.5) 10 (2.7) 0.138 CVA 50 (8.9) 15 (7.7) 35 (9.6) 0.564 Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) <0.001					
Liver cirrhosis			18 (9.3)	31 (8.5)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			22 (11.3)	39 (10.7)	0.925
Dementia 19 (3.4) 4 (2.1) 15 (4.1) 0.305 Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) <0.001			1 (0.5)		
Bedridden 21 (3.8) 5 (2.6) 16 (4.4) 0.403 Malignancy 129 (23.1) 26 (13.4) 103 (28.2) <0.001 Cardiac arrest events, n(%)		50 (8.9)	15 (7.7)		0.564
Malignancy 129 (23.1) 26 (13.4) 103 (28.2) <0.001 Cardiac arrest events, n(%) Source 0.561 OHCA 348 (62.2) 123 (63.4) 225 (61.6) IHCA 162 (29.0) 59 (30.4) 103 (28.2) Transfer 49 (8.8) 12 (6.2) 37 (10.1) Witnessed collapse 482 (86.2) 179 (92.3) 303 (83.0) 0.004 Initial shockable rhythm 196 (35.1) 104 (53.6) 92 (25.2) <0.001		19 (3.4)		15 (4.1)	0.305
Cardiac arrest events, n(%) Source OHCA $348 (62.2)$ $123 (63.4)$ $225 (61.6)$ IHCA $162 (29.0)$ $59 (30.4)$ $103 (28.2)$ Transfer $49 (8.8)$ $12 (6.2)$ $37 (10.1)$ Witnessed collapse $482 (86.2)$ $179 (92.3)$ $303 (83.0)$ 0.004 Initial shockable rhythm $196 (35.1)$ $104 (53.6)$ $92 (25.2)$ 0.001 Pre-hospital ROSC $14 (13.2)$ 0.001 Total CPR duration (min) 0.19 ± 7.3 $0.15.2 \pm 6.0$ $0.25.8$ $0.24 (6.8)$ 0.001 CPR >10 min $0.16 (92.3)$ $0.168 (86.6)$ $0.348 (95.3)$ 0.001 Repeated CPR $0.10 (19.5)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.23 (11.9)$ $0.33 (11.9)$ 0.33			5 (2.6)	16 (4.4)	0.403
Source OHCA 348 (62.2) 123 (63.4) 225 (61.6) HCA 162 (29.0) 59 (30.4) 103 (28.2) Transfer 49 (8.8) 12 (6.2) 37 (10.1) Witnessed collapse 482 (86.2) 179 (92.3) 303 (83.0) 0.004 Initial shockable rhythm 196 (35.1) 104 (53.6) 92 (25.2) <0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) <0.001 Total CPR duration (min) 21.9 ± 7.3 15.2 ± 6.0 25.4 ± 7.6 <0.001 CPR >10 min 516 (92.3) 168 (86.6) 348 (95.3) <0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Epinephrine ≥3 mg 230 (41.1) 45 (23.2) 185 (50.7) <0.001 ScAHP severity Low (<150) 159 (28.4) 101 (52.1) 58 (15.9) <0.001 Moderate (150-200) 212 (37.9) 67 (34.5) 145 (39.7) 0.250 High (>200) 164 (29.3) 18 (9.3) 146 (40.0) <0.001 Post-arrest care, median (IQR) ROSC DBP, mmHg 119 (99−154) 132 (104−161) 114 (84.0−149) 0.001 TTM 210 (37.6) 66 (34.0) 144 (39.5) 0.242 APACHE II score 34 (27.5−39.0) 30 (19.5−36.0) 35 (31−40) <0.001 Hemoglobin, g/dL 12.6 (10.3−15.1) 14.3 (11.0−16.0) 12.0 (9.7−14.4) <0.001 Troponin-T, ng/L 36.4 (16.0−116) 25.8 (14.3−71.1) 53.4 (20.1−142) <0.001 Post-arcia caid, mmol/L 9.38 (6.23−12.3) 8.04 (5.34−11.4) 9.84 (6.69−12.6) <0.001 Phy value 7.12 (7.00−7.25) 7.20 (7.05−7.29) 7.08 (6.98−7.20) <0.001		129 (23.1)	26 (13.4)	103 (28.2)	< 0.001
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Cardiac arrest events, n(%)				
IHCA 162 (29.0) 59 (30.4) 103 (28.2) Transfer 49 (8.8) 12 (6.2) 37 (10.1) Witnessed collapse 482 (86.2) 179 (92.3) 303 (83.0) 0.004 Initial shockable rhythm 196 (35.1) 104 (53.6) 92 (25.2) <0.001					0.561
Transfer 49 (8.8) 12 (6.2) 37 (10.1) Witnessed collapse 482 (86.2) 179 (92.3) 303 (83.0) 0.004 Initial shockable rhythm 196 (35.1) 104 (53.6) 92 (25.2) <0.001 Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) <0.001 Total CPR duration (min) 21.9 ± 7.3 15.2 ± 6.0 25.4 ± 7.6 <0.001 CPR >10 min 516 (92.3) 168 (86.6) 348 (95.3) <0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Epinephrine ≥3 mg 230 (41.1) 45 (23.2) 185 (50.7) <0.001 Cardiogenic arrest 302 (54.0) 133 (68.6) 169 (46.3) <0.001 SCAHP severity Low (<150) 159 (28.4) 101 (52.1) 58 (15.9) <0.001 Moderate (150−200) 164 (29.3) 18 (9.3) 146 (40.0) <0.001 Post-arrest care, median (IQR) ROSC SBP, mmHg 119 (99−154) 132 (104−161) 114 (84.0−149) <0.001 TM ROSC DBP, mmHg 69 (54.0−88.5) 79 (62.0−94.5) 64.5 (50.0−84.0) <0.001 TM 210 (37.6) 66 (34.0) 144 (39.5) 0.242 APACHE II score 34 (27.5−39.0) 30 (19.5−36.0) 35 (31−40) <0.001 Troponin-T, ng/L 36.4 (16.0−116) 25.8 (14.3−71.1) 53.4 (20.1−142) <0.001 Lactic acid, mmol/L 9.38 (6.23−12.3) 8.04 (5.34−11.4) 9.84 (6.69−12.6) <0.001 pH value 7.12 (7.00−7.25) 7.20 (7.05−7.29) 7.08 (6.98−7.20) <0.001					
Witnessed collapse $482 (86.2)$ $179 (92.3)$ $303 (83.0)$ 0.004 Initial shockable rhythm $196 (35.1)$ $104 (53.6)$ $92 (25.2)$ <0.001 Pre-hospital ROSC $74 (13.2)$ $50 (25.8)$ $24 (6.8)$ <0.001 Total CPR duration (min) 21.9 ± 7.3 15.2 ± 6.0 25.4 ± 7.6 <0.001 CPR >10 min $516 (92.3)$ $168 (86.6)$ $348 (95.3)$ <0.001 Repeated CPR $109 (19.5)$ $23 (11.9)$ $86 (23.6)$ 0.001 Epinephrine ≥3 mg $230 (41.1)$ $45 (23.2)$ $185 (50.7)$ <0.001 Cardiogenic arrest $302 (54.0)$ $133 (68.6)$ $169 (46.3)$ <0.001 sCAHP severity Low (<150) $159 (28.4)$ $101 (52.1)$ $58 (15.9)$ <0.001 Moderate (150-200) $212 (37.9)$ $67 (34.5)$ $145 (39.7)$ 0.250 High (>200) $164 (29.3)$ $18 (9.3)$ $146 (40.0)$ <0.001 Post-arrest care, median (IQR) ROSC SBP, mmHg $119 (99-154)$ $132 (104-161)$ $114 (84.0-149)$ <0.001 TTM $210 (37.6)$ $66 (34.0)$ $144 (39.5)$ 0.242 APACHE II score $34 (27.5-39.0)$ $30 (19.5-36.0)$ $35 (31-40)$ <0.001 Hemoglobin, g/dL $12.6 (10.3-15.1)$ $14.3 (11.0-16.0)$ $12.0 (9.7-14.4)$ <0.001 Troponin-T, ng/L $36.4 (16.0-116)$ $25.8 (14.3-71.1)$ $53.4 (20.1-142)$ <0.001 Lactic acid, mmol/L $9.38 (6.23-12.3)$ $8.04 (5.34-11.4)$ $9.84 (6.69-12.6)$ <0.001 pH value $7.12 (7.00-7.25)$ $7.20 (7.05-7.29)$ $7.08 (6.98-7.20)$ <0.001					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$					
Pre-hospital ROSC 74 (13.2) 50 (25.8) 24 (6.8) <0.001 Total CPR duration (min) 21.9 ± 7.3 15.2 ± 6.0 25.4 ± 7.6 <0.001 CPR >10 min 516 (92.3) 168 (86.6) 348 (95.3) <0.001 Repeated CPR 109 (19.5) 23 (11.9) 86 (23.6) 0.001 Epinephrine ≥3 mg 230 (41.1) 45 (23.2) 185 (50.7) <0.001 Cardiogenic arrest 302 (54.0) 133 (68.6) 169 (46.3) <0.001 SCAHP severity Low (<150) 159 (28.4) 101 (52.1) 58 (15.9) 0.250 High (>200) 164 (29.3) 18 (9.3) 146 (40.0) <0.001 Post-arrest care, median (IQR) ROSC SBP, mmHg 119 (99−154) 132 (104−161) 114 (84.0−149) <0.001 POSt-arrest care, median (IQR) TIM 210 (37.6) 66 (34.0) 144 (39.5) 0.242 APACHE II score 34 (27.5−39.0) 30 (19.5−36.0) 35 (31−40) <0.001 Troponin-T, ng/L 36.4 (16.0−116) 25.8 (14.3−71.1) 53.4 (20.1−142) <0.001 Post-actic acid, mmol/L 9.38 (6.23−12.3) 8.04 (5.34−11.4) 9.84 (6.69−12.6) <0.001 pH value 7.12 (7.00−7.25) 7.20 (7.05−7.29) 7.08 (6.98−7.20) <0.001					
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	_				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$					
Epinephrine ≥3 mg 230 (41.1) 45 (23.2) 185 (50.7) <0.001 Cardiogenic arrest 302 (54.0) 133 (68.6) 169 (46.3) <0.001 sCAHP severity					
Cardiogenic arrest 302 (54.0) 133 (68.6) 169 (46.3) <0.001 sCAHP severity Low (<150) 159 (28.4) 101 (52.1) 58 (15.9) <0.001 Moderate (150–200) 212 (37.9) 67 (34.5) 145 (39.7) 0.250 High (>200) 164 (29.3) 18 (9.3) 146 (40.0) <0.001 Post-arrest care, median (IQR) ROSC SBP, mmHg 119 (99–154) 132 (104–161) 114 (84.0–149) <0.001 ROSC DBP, mmHg 69 (54.0–88.5) 79 (62.0–94.5) 64.5 (50.0–84.0) <0.001 TTM 210 (37.6) 66 (34.0) 144 (39.5) 0.242 APACHE II score 34 (27.5–39.0) 30 (19.5–36.0) 35 (31–40) <0.001 Hemoglobin, g/dL 12.6 (10.3–15.1) 14.3 (11.0–16.0) 12.0 (9.7–14.4) <0.001 Troponin-T, ng/L 36.4 (16.0–116) 25.8 (14.3–71.1) 53.4 (20.1–142) <0.001 Lactic acid, mmol/L 9.38 (6.23–12.3) 8.04 (5.34–11.4) 9.84 (6.69–12.6) <0.001 pH value 7.12 (7.00–7.25) 7.20 (7.05–7.29) 7.08 (6.98–7.20) <0.001	_		` ′		
sCAHP severity Low (<150) 159 (28.4) 101 (52.1) 58 (15.9) <0.001 Moderate (150–200) 212 (37.9) 67 (34.5) 145 (39.7) 0.250 High (>200) 164 (29.3) 18 (9.3) 146 (40.0) <0.001					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	_	302 (54.0)	133 (68.6)	169 (46.3)	< 0.001
Moderate (150–200) 212 (37.9) 67 (34.5) 145 (39.7) 0.250 High (>200) 164 (29.3) 18 (9.3) 146 (40.0) <0.001					
High (>200) 164 (29.3) 18 (9.3) 146 (40.0) <0.001 Post-arrest care, median (IQR) ROSC SBP, mmHg 119 (99–154) 132 (104–161) 114 (84.0–149) <0.001					
Post-arrest care, median (IQR) ROSC SBP, mmHg 119 (99–154) 132 (104–161) 114 (84.0–149) <0.001	` ′				
ROSC SBP, mmHg 119 (99–154) 132 (104–161) 114 (84.0–149) <0.001		164 (29.3)	18 (9.3)	146 (40.0)	< 0.001
ROSC DBP, mmHg 69 (54.0–88.5) 79 (62.0–94.5) 64.5 (50.0–84.0) <0.001					
TTM 210 (37.6) 66 (34.0) 144 (39.5) 0.242 APACHE II score 34 (27.5–39.0) 30 (19.5–36.0) 35 (31–40) <0.001 Hemoglobin, g/dL 12.6 (10.3–15.1) 14.3 (11.0–16.0) 12.0 (9.7–14.4) <0.001 Troponin-T, ng/L 36.4 (16.0–116) 25.8 (14.3–71.1) 53.4 (20.1–142) <0.001 Lactic acid, mmol/L 9.38 (6.23–12.3) 8.04 (5.34–11.4) 9.84 (6.69–12.6) <0.001 pH value 7.12 (7.00–7.25) 7.20 (7.05–7.29) 7.08 (6.98–7.20) <0.001				` ′	
APACHE II score 34 (27.5–39.0) 30 (19.5–36.0) 35 (31–40) <0.001 Hemoglobin, g/dL 12.6 (10.3–15.1) 14.3 (11.0–16.0) 12.0 (9.7–14.4) <0.001 Troponin-T, ng/L 36.4 (16.0–116) 25.8 (14.3–71.1) 53.4 (20.1–142) <0.001 Lactic acid, mmol/L 9.38 (6.23–12.3) 8.04 (5.34–11.4) 9.84 (6.69–12.6) <0.001 pH value 7.12 (7.00–7.25) 7.20 (7.05–7.29) 7.08 (6.98–7.20) <0.001	-	,	` '	` '	
Hemoglobin, g/dL 12.6 (10.3–15.1) 14.3 (11.0–16.0) 12.0 (9.7–14.4) <0.001		* *	` ′	` ′	
Troponin-T, ng/L 36.4 (16.0–116) 25.8 (14.3–71.1) 53.4 (20.1–142) <0.001		` '			
Lactic acid, mmol/L 9.38 (6.23–12.3) 8.04 (5.34–11.4) 9.84 (6.69–12.6) <0.001 pH value 7.12 (7.00–7.25) 7.20 (7.05–7.29) 7.08 (6.98–7.20) <0.001		* * * * * * * * * * * * * * * * * * * *			
pH value 7.12 (7.00–7.25) 7.20 (7.05–7.29) 7.08 (6.98–7.20) <0.001				` '	
HCO ₃ , mmol/L 19.0 (15.4–22.9) 19.2 (15.4–22.8) 18.9 (15.4–23.0) 0.853	-				
Data presented as no. (%) or as median (IOR).			19.2 (15.4–22.8)	18.9 (15.4–23.0)	0.853

Data presented as no. (%) or as median (IQR).

COPD, chronic obstructive pulmonary disease; CPR, cardiopulmonary resuscitation; CVA, cerebrovascular accident; DBP, diastolic blood pressure; ESRD, end stage renal disease; IHCA, in-hospital cardiac arrest; IQR, interquartile range; OHCA, out-of-hospital cardiac arrest; ROSC, return of spontaneous circulation; SBP, systolic blood pressure; sCAHP, simplified cardiac arrest hospital prognosis; TTM, therapeutic temperature management; APACHE, acute physiology and chronic health evaluation.



Table 2. Characteristics of cerebral computed tomography between groups.

	All patients	Favorable outcome	Poor outcome	- p-value
	(n = 559)	(n = 194)	(n = 365)	- p-value
GWR, Median (IQR)	1.29 (1.21–1.37)	1.37 (1.30–1.43)	1.25 (1.18–1.31)	< 0.001
Average HU of Putamen	34.8 (32.2–27.1)	35.8 (34.3–38.0)	34.1 (31.3–36.2)	< 0.001
Average HU of Corpus Callosum	27.0 (24.9–29.0)	26.4 (24.7–28.2)	27.2 (25.0–29.4)	0.002
Area ratio of the ventricle and the whole brain, Median (IQR)	0.110 (0.086-0.141)	0.108 (0.087-0.136)	0.110 (0.085-0.143)	0.449
Area of 2 lateral ventricles, mm ²	7897 (6211–10,226)	7802 (6239–9947)	7963 (6195–10,298)	0.523
Area of the whole brain, mm ²	73,095 (69,540–76,643)	73,351 (70,011–76,527)	72,727 (69,252–76,697)	0.480
Area of third ventricle, mm ²	714 (524–993)	670 (500–926)	741 (552–1014)	0.057
Area of fourth ventricle, mm ²	432 (331–561)	461 (380–617)	413 (313–545)	< 0.001
Anteroposterior diameter of fourth ventricle, cm	0.89 (0.75–1.07)	0.95 (0.80-1.11)	0.86 (0.71–1.03)	< 0.001
Abnormal MTLA (%)	26 (4.7)	7 (3.6)	19 (5.2)	0.520

Data presented as no. (%) or as median (IQR).

HU, Hounsfield unit; GWR, grey-to-white matter ratio; MTLA, medial temporal lobe atrophy; IQR, interquartile range.

Table 3. Characteristics of cerebral computed tomography between different severity groups based on sCAHP score.

	Low severity	Moderate severity	High severity	<i>p</i> -value	p trend
GWR	1.339 (1.264–1.394)	1.293 (1.216–1.367)	1.253 (1.162–1.320)	< 0.001	< 0.001
Area ratio of the ventricle and the whole brain	0.104 (0.078-0.125)	0.127 (0.088-0.145)	0.117 (0.086–0.143)	0.008	0.111
Area of third ventricle, mm ²	722.8 (491.0–902.0)	811.4 (548.3–1031)	783.7 (563.5–991.8)	0.064	0.137
Area of fourth ventricle, mm ²	486.8 (364.0–627.0)	460.8 (345.3–549.3)	435.0 (307.3–532.3)	0.065	0.019
Anteroposterior diameter of fourth ventricle, cm	0.922 (0.770-1.090)	0.919 (0.800-1.070)	0.854 (0.700-1.023)	0.019	0.014
Abnormal MTLA (%)	9 (5.7)	11 (5.2)	3 (1.8)	0.170	0.089

Data presented as no. (%) or as median (IQR).

GWR, grey-to-white matter ratio; MTLA, medial temporal lobe atrophy; IQR, interquartile range.

Table 4. Predictive ability of GWR, severity score and their combination.

	· · · · · · · · · · · · · · · · · · ·	· •	
Predictive marker	GWR	sCAHP	sCAHP + GWR
Overall	0.81 (0.78-0.85)*	0.76 (0.72–0.80)*	0.86 (0.83-0.89)
Subgroup			
Age $<$ 65	0.85 (0.80-0.89)	0.73 (0.66–0.79)	0.86 (0.82-0.91)
Age ≥65	0.80 (0.75-0.85)	0.77 (0.71–0.82)	0.85 (0.81-0.90)
OHCA	0.85 (0.82-0.89)	0.80 (0.75-0.84)	0.90 (0.88-0.93)
IHCA	0.73 (0.66-0.81)	0.71 (0.63-0.78)	0.79 (0.72–0.86)
Nonshockable	0.83 (0.79-0.88)	0.79 (0.74–0.84)	0.88 (0.84-0.91)
Shockable	0.79 (0.73-0.86)	0.71 (0.64-0.78)	0.84 (0.78-0.89)
Non-TTM	0.81 (0.77-0.86)	0.74 (0.69-0.79)	0.85 (0.81-0.89)
TTM	0.82 (0.76-0.87)	0.81 (0.75-0.87)	0.88 (0.84-0.92)

^{*}p < 0.001 when compared with sCAHP + GWR.

OHCA, out-of-hospital cardiac arrest; IHCA, in-hospital cardiac arrest; TTM, targeted temperature management; sCAHP, simplified cardiac arrest hospital prognosis; GWR, grey-to-white matter ratio.

4. Discussion

In this retrospective cohort study, we observed that cardiac arrest survivors with poor neurological recover were associated with lower GWR and fourth ventricle size. The GWR and fourth ventricle size decreased as postarrest severity increased in cardiac arrest survivors. Combining GWR with sCAHP score significantly improved predictive ability (vs either alone), particularly for patients with OHCA, those with initial nonshockable rhythm, and those receiving TTM.

Various neuroimaging tools have been developed for neuroprognostication. Several studies have validated GWR as a marker of neurological outcomes of cardiac arrest [11–13]. The Coronary Angiography After Cardiac Arrest trial included only patients with OHCA with initial shockable rhythm; the results of a post hoc analysis performed in this trial indicated GWR to be a poor neurological prognostic marker [31]. In our study, the GWR to have fair value for neuroprognostication. The difference in these results regarding the predictive ability of GWR might originate from






Fig. 2. The predictive performance of GWR and severity score for poor neurological outcome. ROC, receiver operating characteristic; AUC, area under the receiver operating characteristic curve; GWR, gray-to-white ratio; sCAHP, simplified cardiac arrest hospital prognosis.

differences in the inclusion criteria of the aforementioned study and ours. Very few studies have focused on neurological outcome prediction based on brain ventricle characteristics, and the reported results are diverse. Lee et al. [15] included cardiac arrest patients who underwent TTM and reported that a decrease in third ventricle area may indicate favorable neurological outcomes but observed no significant differences in the fourth ventricle area. Our findings suggested similar trends for third ventricle area, but statistical significance was not reached. Cerebral edema may affect the aqueduct connecting the third and fourth ventricles. Even mild edema narrows the aqueduct and cause an obstruction. The third ventricle may consequently increase in size. However, another study of OHCA patients who received therapeutic hypothermia reported no neuroprognostic value of third ventricle area [14], yet patients with larger fourth ventricle areas had more favorable neurological prognoses. Our study showed similar results. Welldesigned studies are warranted to clarify these inconclusive results regarding third and fourth ventricle area. In summary, more severe brain edema appears to be associated with lower GWR; however, the correlation between fourth ventricle area and neurological outcomes requires further study. The VBR as well as MTLA scores were analyzed on the basis of the hypothesis that brain atrophy may complicate brain edema and intracranial pressure and thus influence neurological outcomes. However, no significant results were observed for any of these measurements.

GWR has been combined with other laboratory or clinical assessments, such as imaging [32,33], electroencephalography [34], and blood tests [35], to improve its prognostic performance. Such combinations improved the prediction of neurological outcomes. Although various

scoring systems based on medical history and CPR events have been developed, few studies have evaluated the performance of GWR in combination with a clinical scoring system for predicting neurological outcomes after cardiac arrest [25]. We evaluated the ability of the combination of GWR and sCAHP score for neuroprognostication, which was superior to that of either indicator alone. The CAST score, proposed by Nishikimi *et al.* [36], includes GWR and also exhibited good predictive ability (AUC = 0.971) in external validation.

In subgroup analysis, the predictions of GWR, sC-AHP, and their combination were more accurate for patients with OHCA than for those with IHCA. These findings are consistent with those of previous studies. Yeh et al. [10] used GWR to predict survival and neurological outcomes in OHCA survivors and reported promising results. However, Ong et al. [37] reported no predictive power of GWR for survivors of IHCA. Carrick et al. [38] performed a systemic review of clinical predictive models of sudden cardiac arrest; predictive performance was better for patients with OHCA than for those with IHCA. This result might be due to patients with IHCA receiving immediate medical attention and advanced cardiac life support, unlike patients with OHCA; thus, hypoxic-ischemic brain injury was less severe among the patients with IHCA [10,37,38]. Therefore, GWR is more effective for predicting the neurological outcomes of OHCA survivors. Also need to be mentioned that sCAHP scores are more suitable for survivors of OHCA than of IHCA, since the sCAHP score is established on data from OHCA survivors [24].

5. Limitations

This study has some limitations. First, because of the retrospective nature, selection bias was unavoidable; moreover, unidentified confounding factors might have been present. Second, although the intraclass correlation coefficient was high, practical measurements of neuroimaging parameters may vary across raters. Third, 12 of the total 559 included patients received cardiac catheterization before the cerebral CT, and the contrast used in the coronary angiography may influence HU value and GWR in some case reports [39,40]. Fourth, the Coma Recovery Scale-Revised (CRS-R) score may be more accurate than CPC scale in evaluating the neurological outcome of cardiac arrest survivors with disorder of consciousness [41]. However, due to the retrospective nature, some certain functional tests needed for the calculation, such as auditory or visual function, were not recorded. Finally, this study was conducted at a single tertiary medical center in an urban region; however, the protocol for the treatment and transport of patients with cardiac arrest may be different from those in rural regions or at primary care centers. Thus, in different clinical settings the prognostic scoring system should be applied with caution.



6. Conclusions

In cardiac arrest survivors, GWR and the size of the fourth ventricle were associated with neurological recovery. GWR as well as the area and anteroposterior diameter of the fourth ventricle decreased as postarrest severity increases. Combining GWR and sCAHP score may improve the ability of neuroprognostication.

Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author Contributions

We declare that we participated in this study that MST, HNO, CHH, WTChe, contributed to the study concept and design; MST contributed to the acquisition of the data; MST, SSH, YTT, HYL analyzed and interpreted the data; MST, SSH draft the manuscript; MST, CHH, WTChe, WJC, WTCha, HNO provided critical revision of the manuscript for important intellectual content; MST, SSH, YTT performed the statistical analysis; CHH, WTCha, WJC supervised the study.

Ethics Approval and Consent to Participate

The retrospective observational study, approved by the Institutional Review Boards of National Taiwan University Hospital (NTUH) (202112205RINB). Informed consent was waived.

Acknowledgment

Not applicable.

Funding

This research received no external funding.

Conflict of Interest

The authors declare no conflict of interest. Chien-Hua Huang is serving as Guest Editor of this journal. We declare that Chien-Hua Huang had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Zhonghua Sun.

References

- [1] Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, *et al.* Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018; 137: e67–e492.
- [2] Holmberg MJ, Ross CE, Fitzmaurice GM, Chan PS, Duval-Arnould J, Grossestreuer AV, et al. Annual Incidence of Adult and Pediatric In-Hospital Cardiac Arrest in the United States. Circulation. Cardiovascular Quality and Outcomes. 2019; 12: e005580.
- [3] Wang CY, Wang JY, Teng NC, Chao TT, Tsai SL, Chen CL, et

- al. The secular trends in the incidence rate and outcomes of outof-hospital cardiac arrest in Taiwan—a nationwide populationbased study. PLoS ONE. 2015; 10: e0122675.
- [4] Moulaert VRMP, Verbunt JA, van Heugten CM, Wade DT. Cognitive impairments in survivors of out-of-hospital cardiac arrest: a systematic review. Resuscitation. 2009; 80: 297–305.
- [5] Geocadin RG, Callaway CW, Fink EL, Golan E, Greer DM, Ko NU, et al. Standards for Studies of Neurological Prognostication in Comatose Survivors of Cardiac Arrest: A Scientific Statement From the American Heart Association. Circulation. 2019; 140: e517–e542.
- [6] Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020; 142: S366–S468.
- [7] Taccone F, Cronberg T, Friberg H, Greer D, Horn J, Oddo M, *et al.* How to assess prognosis after cardiac arrest and therapeutic hypothermia. Critical Care. 2014; 18: 202.
- [8] Tsai M, Chen W, Chen W, Tien Y, Chang W, Ong H, et al. Should we Prolong the Observation Period for Neurological Recovery after Cardiac Arrest? Critical Care Medicine. 2022; 50: 389– 397
- [9] Chen WT, Tsai MS, Huang CH, Chang WT, Chen WJ. Protocolized Post-Cardiac Arrest Care with Targeted Temperature Management. Acta Cardiologica Sinica. 2022; 38: 391–399.
- [10] Yeh HF, Ong HN, Lee BC, Huang CH, Huang CC, Chang WT, et al. The Use of Gray-White-Matter Ratios May Help Predict Survival and Neurological Outcomes in Patients Resuscitated From Out-of-Hospital Cardiac Arrest. Journal of Acute Medicine. 2020; 10: 77–89.
- [11] Wang WJ, Cui J, Lv GW, Feng SY, Zhao Y, Zhang SL, et al. Prognostic Values of the Gray-to-White Matter Ratio on Brain Computed Tomography Images for Neurological Outcomes after Cardiac Arrest: a Meta-Analysis. BioMed Research International. 2020; 2020: 7949516.
- [12] Lopez Soto C, Dragoi L, Heyn CC, Kramer A, Pinto R, Adhikari NKJ, et al. Imaging for Neuroprognostication after Cardiac Arrest: Systematic Review and Meta-analysis. Neurocritical Care. 2020; 32: 206–216.
- [13] Na MK, Kim W, Lim TH, Jang B, Cho Y, Choi K, *et al.* Gray matter to white matter ratio for predicting neurological outcomes in patients treated with target temperature management after cardiac arrest: a systematic review and meta-analysis. Resuscitation. 2018; 132: 21–28.
- [14] Lee BK, Callaway CW, Coppler PJ, Rittenberger JC. Pittsburgh Post-Cardiac Arrest Service. The prognostic performance of brain ventricular characteristic differ according to sex, age, and time after cardiac arrest in comatose out-of-hospital cardiac arrest survivors. Resuscitation. 2020; 154: 69–76.
- [15] Lee DH, Lee BK, Jeung KW, Jung YH, Cho YS, Cho IS, *et al.* Relationship between ventricular characteristics on brain computed tomography and 6-month neurologic outcome in cardiac arrest survivors who underwent targeted temperature management. Resuscitation. 2018; 129: 37–42.
- [16] Velickaite V, Ferreira D, Cavallin L, Lind L, Ahlström H, Kilander L, et al. Medial temporal lobe atrophy ratings in a large 75-year-old population-based cohort: gender-corrected and education-corrected normative data. European Radiology. 2018; 28: 1739–1747.
- [17] Ørbo MC, Aslaksen PM, Anke A, Tande PM, Vangberg TR. Cortical Thickness and Cognitive Performance after out-of-Hospital Cardiac Arrest. Neurorehabilitation and Neural Repair. 2019; 33: 296–306.
- [18] Ørbo MC, Vangberg TR, Tande PM, Anke A, Aslaksen PM. Memory performance, global cerebral volumes and hippocam-



- pal subfield volumes in long-term survivors of out-of-Hospital Cardiac Arrest. Resuscitation. 2018; 126: 21–28.
- [19] Stamenova V, Nicola R, Aharon-Peretz J, Goldsher D, Kapeliovich M, Gilboa A. Long-term effects of brief hypoxia due to cardiac arrest: Hippocampal reductions and memory deficits. Resuscitation. 2018; 126: 65–71.
- [20] Horstmann A, Frisch S, Jentzsch RT, Muller K, Villringer A, Schroeter ML. Resuscitating the heart but losing the brain: Brain atrophy in the aftermath of cardiac arrest. Neurology. 2010; 74: 306–312.
- [21] Lachance B, Wang Z, Badjatia N, Jia X. Somatosensory Evoked Potentials and Neuroprognostication after Cardiac Arrest. Neurocritical Care. 2020; 32: 847–857.
- [22] Amorim E, Ghassemi MM, Lee JW, Greer DM, Kaplan PW, Cole AJ, et al. Estimating the False Positive Rate of Absent Somatosensory Evoked Potentials in Cardiac Arrest Prognostication. Critical Care Medicine. 2018; 46: e1213–e1221.
- [23] Wang C, Huang C, Chang W, Tsai M, Yu P, Wu Y, et al. Prognostic performance of simplified out-of-hospital cardiac arrest (OHCA) and cardiac arrest hospital prognosis (CAHP) scores in an East Asian population: a prospective cohort study. Resuscitation. 2019; 137: 133–139.
- [24] Maupain C, Bougouin W, Lamhaut L, Deye N, Diehl J, Geri G, *et al.* The CAHP (Cardiac Arrest Hospital Prognosis) score: a tool for risk stratification after out-of-hospital cardiac arrest. European Heart Journal. 2016; 37: 3222–3228.
- [25] Nishikimi M, Matsuda N, Matsui K, Takahashi K, Ejima T, Liu K, et al. CAST: a new score for early prediction of neurological outcomes after cardiac arrest before therapeutic hypothermia with high accuracy. Intensive Care Medicine. 2016; 42: 2106–2107.
- [26] Nishikimi M, Ogura T, Nishida K, Takahashi K, Nakamura M, Matsui S, et al. External validation of a risk classification at the emergency department of post-cardiac arrest syndrome patients undergoing targeted temperature management. Resuscitation. 2019; 140: 135–141.
- [27] Tsuchida T, Ono K, Maekawa K, Wada T, Katabami K, Yoshida T, et al. Simultaneous external validation of various cardiac arrest prognostic scores: a single-center retrospective study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. 2021; 29: 117.
- [28] Perkins GD, Jacobs IG, Nadkarni VM, Berg RA, Bhanji F, Biarent D, et al. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update of the Utstein Resuscitation Registry Templates for Out-of-Hospital Cardiac Arrest: a statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian and New Zealand Council on Resuscitation, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, Resuscitation Council of Asia); and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Circulation. 2015; 132: 1286–1300.

- [29] Choplin RH, Boehme JM, Maynard CD. Picture archiving and communication systems: an overview. RadioGraphics. 1992; 12: 127–129.
- [30] Haak D, Page C, Deserno TM. A Survey of DICOM Viewer Software to Integrate Clinical Research and Medical Imaging. Journal of Digital Imaging. 2016; 29: 206–215.
- [31] Adriaansens KO, Jewbali LSD, Lemkes JS, Spoormans EM, Meuwissen M, Blans MJ, et al. Routine reporting of grey-white matter differentiation in early brain computed tomography in comatose patients after cardiac arrest: a substudy of the COACT trial. Resuscitation. 2022; 175: 13–18.
- [32] Jeon CH, Park JS, Lee JH, Kim H, Kim SC, Park KH, et al. Comparison of brain computed tomography and diffusion-weighted magnetic resonance imaging to predict early neurologic outcome before target temperature management comatose cardiac arrest survivors. Resuscitation. 2017; 118: 21–26.
- [33] Chae MK, Ko E, Lee JH, Lee TR, Yoon H, Hwang SY, et al. Better prognostic value with combined optic nerve sheath diameter and grey-to-white matter ratio on initial brain computed tomography in post-cardiac arrest patients. Resuscitation. 2016; 104: 40-45
- [34] Youn CS, Callaway CW, Rittenberger JC, Post Cardiac Arrest Service. Combination of initial neurologic examination, quantitative brain imaging and electroencephalography to predict outcome after cardiac arrest. Resuscitation. 2017; 110: 120–125.
- [35] Lee BK, Jeung KW, Lee HY, Jung YH, Lee DH. Combining brain computed tomography and serum neuron specific enolase improves the prognostic performance compared to either alone in comatose cardiac arrest survivors treated with therapeutic hypothermia. Resuscitation. 2013; 84: 1387–1392.
- [36] Nishikimi M, Matsuda N, Matsui K, Takahashi K, Ejima T, Liu K, et al. A novel scoring system for predicting the neurologic prognosis prior to the initiation of induced hypothermia in cases of post-cardiac arrest syndrome: the CAST score. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. 2017; 25: 49.
- [37] Ong HN, Chen WJ, Chuang PY, Lee BC, Huang CH, Huang CC, et al. Prognosis Value of Gray-White-Matter Ratios in Comatose Survivors After In-Hospital Cardiac Arrest. Journal of Acute Medicine. 2020; 10: 9–19.
- [38] Carrick RT, Park JG, McGinnes HL, Lundquist C, Brown KD, Janes WA, et al. Clinical Predictive Models of Sudden Cardiac Arrest: a Survey of the Current Science and Analysis of Model Performances. Journal of the American Heart Association. 2020; 9: e017625.
- [39] Khan SM, Ho DW, Lazar JM, Marmur J. Cerebral contrast retention after difficult cardiac catheterization: Case report. SAGE Open Medical Case Reports. 2014; 2: 2050313X14530283.
- [40] Huda SA, Ahmed M, Sampat PJ, Ibeche B, Sharma B. Contrast Extravasation Mimicking Subarachnoid Hemorrhage after Cardiac Catheterization. Cureus. 2020; 12: e9212.
- [41] Seel RT, Sherer M, Whyte J, Katz DI, Giacino JT, Rosenbaum AM, et al. Assessment scales for disorders of consciousness: evidence-based recommendations for clinical practice and research. Archives of Physical Medicine and Rehabilitation. 2010; 91: 1795–1813.

